ILA 1A (Interleukin-1 Receptor Antagonist Protein) ― advanced biological therapy for the treatment of joint diseases

How it works?

ILA 1A (Interleukin-1 Receptor Antagonist Protein) is an advanced biological therapy used to treat joint diseases in animals, mainly horses, dogs and cats. Its purpose is to alleviate inflammation and support the regeneration of joint cartilage, especially in cases of osteoarthritis, sports injuries or chronic inflammation. ILA 1A stands out because it utilises the animal's natural defence mechanisms, making it a safe and well-tolerated alternative to traditional treatments such as steroids or non-steroidal anti-inflammatory drugs.

The mechanism of action of ILA 1A is based on blocking interleukin-1 (IL-1), which is one of the main mediators of inflammation in the joints. IL-1 contributes to cartilage degradation, increased pain, swelling and limited mobility. ILA 1A is an antagonist protein for the IL-1 receptor – it binds to it, preventing IL-1 from triggering an inflammatory response. This inhibits the inflammatory process and gives the joint a chance to regenerate.

Treatment process

Collection of material

The therapy process begins with collecting blood from an animal of the same breed. The blood is placed in special sterile containers containing glass beads that stimulate leukocytes to produce ILA 1A and other anti-inflammatory cytokines. Incubation takes about 24 hours, after which the serum obtained is centrifuged and prepared for administration. The preparation is administered directly into the affected joint, usually in several series, at intervals of several days.

Advantages over conventional therapy

The advantage of ILA 1A therapy is its allogeneic nature – the preparation comes from the body of an animal of the same breed, which minimises the risk of immune reactions or side effects. In addition, ILA 1A has a long-term effect, not only alleviating symptoms but also supporting natural regenerative processes. Unlike steroids, it does not cause tissue weakening or metabolic disorders. ILA-1 therapy does not have the side effects typical of steroid use.

ILA 1A is used primarily in sport horses, which are prone to joint overload, but it is also increasingly used in dogs and cats, especially older animals suffering from chronic joint diseases. The therapy can significantly improve quality of life, increase mobility and delay the progression of the disease.

Summary

In veterinary and human medicine, ILA 1A is considered one of the most promising orthopaedic treatment methods, combining effectiveness with safety. By utilising the body's natural defence mechanisms, this therapy is part of a modern approach to regenerative medicine, which focuses on supporting the body rather than merely masking symptoms.